Vagus Nerve Stimulation in Epilepsy

Stimulation Parameters

HIGH stimulation parameters (0.25-3.5 mA) show significantly better seizure reduction than LOW parameters, with output current limited by side effects like hoarseness and cough, and set based on patient tolerance for a given pulse width 1
Pulse width typically ranges from 500-750 μsec for therapeutic effect, with longer pulse widths being more effective than shorter ones (130 μsec) 1
The standard clinical setting for frequency is 30 Hz, with the HIGH stimulation group showing significantly better seizure reduction than the LOW group (1 Hz) 1
The standard duty cycle setting is 30 sec ON + 5 min OFF, with higher duty cycles showing better efficacy (30 sec ON + 5 min OFF vs. 30 sec ON + 180 min OFF) 1

Approximately 51% of patients experience ≥50% reduction in seizure frequency, with HIGH stimulation groups achieving 24.5-27.9% reduction in seizure frequency compared to 6.1-15.2% in LOW stimulation groups, as supported by the American Academy of Neurology 1
Vagal nerve stimulation (VNS) has demonstrated efficacy in refractory epilepsy, with a mean seizure reduction of approximately 51% 1

VNS primarily activates large myelinated A-fibers, not C-fibers as previously thought, and alters cortical synchronization and modulates brain activity 1
VNS does not require C-fiber activation for anti-epileptic effects 1

On-demand stimulation via magnet can abort approximately 21% of seizures when an aura is detected 1
Closed-loop systems can detect ictal tachycardia and automatically deliver stimulation, with improved efficacy as reported by the American Epilepsy Society 1

Hoarseness, voice alteration, and cough during stimulation periods are common side effects, which tend to diminish over time 1
VNS therapy has potential risks, including infection risk and rare but serious cardiac complications, including bradyarrhythmias, which can occur during lead replacement, emphasizing the need for careful monitoring and proper placement of leads 1
Battery depletion is a critical factor for VNS revision surgery, and replacement is necessary to maintain seizure control in patients with intractable epilepsy, with battery replacement being the most common type of VNS revision surgery, and the current battery level of 25% indicates appropriate timing for replacement 1

Deep brain stimulation (DBS) may be considered if VNS is not feasible or unsuccessful, offering more precise targeting of epileptic networks and potentially higher efficacy rates (60-78% vs 51% with VNS), as recommended by the American Epilepsy Society and reported by the International League Against Epilepsy 1
DBS is a viable alternative for specific epilepsy types, with anterior thalamic nucleus stimulation showing the strongest evidence of efficacy, particularly for focal seizures, with a mean seizure reduction of approximately 60% 1
Combination therapy, including levetiracetam, may be used for urgent control of seizures in patients with refractory epilepsy, as recommended by the Neurocritical Care Society 2

Patients with temporal lobe epilepsy should be evaluated for resective surgery and considered for VNS first, before proceeding to DBS if appropriate 1
DBS should be considered for patients who have failed treatment with at least 2 antiepileptic drugs and are not candidates for resective surgery due to various factors, including epileptogenic focus in eloquent cortex, multiple seizure foci, or high surgical risk, as suggested by the National Institute of Neurological Disorders and Stroke 1
Post-implantation management of DBS includes activating the stimulator 1 month after implantation, adjusting parameters at 4 months post-surgery, and annual reprogramming and monitoring 1
Rapid parameter titration after implantation is recommended, with both continuous stimulation and on-demand stimulation (via magnet swiping) available as options, as recommended by the International League Against Epilepsy 1